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ABSTRACT
Flavin-containing monooxygenases (FMOs) have a significant role in
the metabolism of small molecule pharmaceuticals. Among the five
human FMOs, FMO1, FMO3, and FMO5 are the most relevant to
hepatic drug metabolism. Although age-dependent hepatic protein
expression, based on immunoquantification, has been reported pre-
viously for FMO1 and FMO3, there is very little information on hepatic
FMO5 protein expression. To overcome the limitations of immuno-
quantification, an ultra-performance liquid chromatography (UPLC)-
multiple reaction monitoring (MRM)-based targeted quantitative
proteomic method was developed and optimized for the quantifica-
tion of FMO1, FMO3, and FMO5 in human liver microsomes (HLM). A
post-in silico product ion screening process was incorporated to
verify LC-MRM detection of potential signature peptides before their
synthesis. The developedmethodwas validated bycorrelatingmarker
substrate activity and protein expression in a panel of adult individual
donor HLM (age 39–67 years). Themean (range) protein expression of
FMO3 and FMO5 was 46 (26–65) pmol/mg HLM protein and 27 (11.5–
49) pmol/mgHLMprotein, respectively. Todemonstratequantification
of FMO1, a panel of fetal individual donor HLM (gestational age 14–20
weeks)wasanalyzed. Themean (range) FMO1protein expressionwas
7.0 (4.9–9.7) pmol/mg HLM protein. Furthermore, the ontogenetic
protein expressionof FMO5wasevaluated in fetal, pediatric, and adult
HLM. The quantification of FMO proteins also was compared using
two different calibration standards, recombinant proteins versus
synthetic signature peptides, to assess the ratio between holoprotein
versus total protein. In conclusion, a UPLC-MRM-based targeted
quantitative proteomic method has been developed for the quantifi-
cation of FMO enzymes in HLM.
Introduction
Flavin-containing monooxygenases (FMOs; EC 1.14.13.8) are FAD-
and NADPH-dependent microsomal enzymes that have a significant role
in the metabolism and detoxification of pharmaceutical, endogenous
substances, and environmental compounds. FMOs catalyze the oxygen-
ation of soft nucleophilic heteroatom-containing (e.g., N, S, and P) organic
substances, converting them to more readily excreted polar metabolites.
Five functional human FMO isozymes have been discovered; among
these, FMOs 1, 3, and 5 are relevant to hepatic drug metabolism (Krueger
and Williams, 2005; Cashman and Zhang, 2006; Mitchell, 2008).
FMO1 and FMO3 are differentially expressed in the liver during
development (i.e., undergo a developmental transition). FMO1
expression, the major fetal isozyme, peaks early in gestation (first
and second trimesters) and gradually decreases to undetectable at birth
(Koukouritaki et al., 2002). In contrast, FMO3 expression, the major adult
isozyme, turns on after birth and increases over time, reaching an adult level
in the early teenage years (Koukouritaki et al., 2002). This differential
enzyme expression has garnered much attention, specifically in terms of
adjusting the dosage of FMO substrate drugs for infants and children
(Yokoi, 2009; Yanni et al., 2010). FMO5mRNA expression in adult liver
exceeds that of FMO3 (Cashman and Zhang, 2006); however, earlier
reports have suggested the opposite (Cashman, 1995, 2000). In addition,
FMO5mRNA expression in fetal livers is approximately one-sixth of that
in adult livers (Cashman and Zhang, 2006). However, the ontogeny of
hepatic FMO5 protein expression has not yet been characterized.
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Traditionally, FMOenzyme quantification has relied on isozyme-specific
antibody-based immunoquantification via Western blots. For absolute
quantification, FMO content has been determined based on FAD content,
the tightly bound prosthetic group required for the catalytic activity of FMO
holoproteins (Lang et al., 1998). Recombinant FMOs (e.g., heterologously
expressed in baculovirus-infected insect cells or Supersomes) have served as
calibration standards (Yeung et al., 2000; Koukouritaki et al., 2002). Thus,
previous studies reported the quantification of FMO holoproteins, rather
than total FMO proteins (i.e., holoprotein + apoprotein).
To overcome the common limitations of immunoquantification
(i.e., cross-reactivity, dynamic range, reproducibility, and multiplex-
ity), liquid chromatography-tandem mass spectrometry (LC-MS/MS)-
and multiple reaction monitoring (MRM)-based targeted quantitative
proteomic methods have been developed for the absolute quantification
of cytochrome P450s (CYPs), UDP-glucuronosyltransferases, and
membrane drug transporters (Fallon et al., 2008; Kamiie et al., 2008;
Li et al., 2008; Wang et al., 2008). However, targeted quantitative
proteomic methods for FMOs have yet to be reported. The term
“absolute” quantification in these publications and the report herein
refers to a type of proteomic quantification that produces protein
concentration or amount, rather than “relative” protein expression
profiles. A targeted quantitative proteomic method for absolute protein
quantification relies on the use of either synthetic signature peptides of
known concentration or signature peptides derived from the tryptic
digest of target proteins of known concentration as calibration standards.
The selection of appropriate signature peptides involves the in silico tryptic
digestion of target proteins, followed by evaluation of the resulting candidate
peptides based on several selection criteria to ensure specificity, stability,
and digestion efficiency (Wang et al., 2008; Michaels and Wang, 2014;
Peng et al., 2015). Candidate signature peptides (usually at least two for each
protein) then can be synthesized and used to tune theMS (typically, a triple-
quadrupole MS) for optimal MRM detection. However, some candidate
signature peptides may not perform optimally because of poor digestion
efficiency, chromatography, or ionization during MS analysis, therefore
rendering expensive signature peptides useless. Hence, it is desirable to
incorporate an additional process(es) to verify candidate signature peptides
after in silico prediction but before their synthesis.
The primary objective of the current study was to develop an ultra-
performance liquid chromatography (UPLC)-MRM-based targeted
quantitative proteomic method for the absolute quantification of FMO1,
FMO3, and FMO5 in human liver microsomes (HLM). The secondary
objective was to evaluate post-in silico product ion screening of the target
protein tryptic digest as a way to verify candidate signature peptides prior
to their synthesis.
Materials and Methods
Chemicals, Enzymes, and Liver Tissues. Optima-grade acetonitrile, water,
formic acid, and acetic acid were obtained from Fisher Scientific (Pittsburgh,
PA). Ammonium bicarbonate, dimethylsulfoxide, dithiothreitol, iodoacetamide,
and cimetidine were purchased from Sigma-Aldrich (St. Louis, MO). Cimetidine
sulfoxide was acquired from Abcam Biochemicals (Cambridge, UK). Famoti-
dine sulfoxide was acquired from Toronto Research Chemicals (Toronto,
Canada). Recombinant human FMO1, FMO3, and FMO5 Supersomes, prepared
from baculovirus-infected insect cells expressing human FMO enzymes,
were purchased from Corning Gentest (Woburn, MA). The FMO concentration
(pmol/ml and pmol/mg protein) of each Supersome, based on the FAD content
determined by an high-performance liquid chromatography-fluorescence
method (Lang et al., 1998), was provided by the supplier. Control Supersomes
(Corning Gentest) contained microsomes from insect cells infected with wild-
type baculovirus. Synthetic unlabeled AQUA Ultimate-grade signature pep-
tides (5 pmol/ml 6 5% by amino acid analysis) were ordered from Thermo
Scientific (Ulm, Germany). Peptide purity (.97%), determined by reverse-phase
high-performance liquid chromatography-ultraviolet (detection wavelength of
215 nm) and matrix-assisted laser desorption/ionization-time of flight MS,
was provided by the manufacturer. Synthetic 13C and 15N stable isotope-
labeled crude signature peptides also were acquired from Thermo Scientific. All
synthetic peptide sequences were confirmed by MS/MS fragmentation analysis
using a Waters Xevo TQ-S triple-quadrupole MS (Milford, MA). Sequencing-
grade modified trypsin was purchased from Promega (Madison, WI). Pooled
HLM (XTreme 200) and nine individual adult donor HLM (Supplemental
Table 1) were purchased from XenoTech, LLC (Lenexa, KS). Liver tissues from
7 fetal (14–20weeks gestation) donors and 16 pediatric (aged 5months–10 years)
donors were obtained from the National Institute of Child Health and Human
Development Brain and Tissue Bank for Developmental Disorders (Contract
#HHSN275200900011C, Ref. No. NO1-HD-9-0011; Baltimore, MD) under an
approved University of North Carolina-Chapel Hill Institutional Review Board
and were used to prepare fetal and pediatric HLM (Supplemental Table 1).
In Silico Selection of FMO Signature Peptides. Candidate tryptic signature
peptides for FMO quantification were selected in silico using criteria described
previously (Wang et al., 2008; Michaels and Wang, 2014; Peng et al., 2015). The
selected candidate peptides for each FMOprotein are listed in (Supplemental Table 2).
Trypsin Digestion. The tryptic digestion of FMO Supersomes and HLMwas
performed as described previously with minor modifications (Wang et al., 2008;
Michaels and Wang, 2014). Briefly, protein samples (30 mg) were reduced in
ammonium bicarbonate buffer (pH 8.0, 50 mM final concentration) containing
dithiothreitol (4 mM final concentration) and heated at 60C for 60 minutes to
denature the proteins. After cooling to room temperature, the samples (90ml total
volume) were alkylated with iodoacetamide (10 mM final concentration) for 20
minutes in the dark before digestion with 1 mg trypsin at 37C for 4 hours unless
stated otherwise. All reactions were carried out in Eppendorf Protein LoBind
microcentrifuge tubes (Hamburg, Germany) to minimize protein and peptide loss
due to binding. Solvent evaporation during the incubations was minimized by
sealing the capped tubeswith parafilm and applying pressurewith an aluminumblock.
To optimize the trypsin digestion protocol, different digestion times (0.5, 1, 2, 4, 6, 8,
12, and 24 hours) and protein-to-trypsin ratios (10, 20, 30, 40, 50, 60, 80, and 100:1)
were examined. Reactions were cold-quenched with storage at 280C. A
mixture of stable isotope-labeled signature peptides (1 ml; internal standards)
was spiked into the thawed samples before loading into a 6C autosampler.
Signature Peptide Verification by Post-In Silico Product Ion Screening.
After vortexing and centrifugation (16,000 g for 10 minutes at 4C), the
supernatants (10 ml) of the quenched digestion mixtures underwent UPLC-MS/
MS analysis. The UPLC-MS/MS instrument, consisting of a Waters Acquity
UPLC I-class binary solvent manager coupled with a Waters Xevo TQ-S triple-
quadrupole MS, was operated under positive electrospray ion mode. Chromato-
graphic separation of the peptides was carried out on a reversed-phase column
(Waters UPLC BEH-C18, 1.7 mm, 2.1 100 mm), fitted with an in-line column
filter and a VanGuard guard-column (Waters). The mobile phases consisted of
(A) water containing 0.1% (v/v) formic acid and (B) acetonitrile containing 0.1%
(v/v) formic acid. A 13.5 minute gradient (0.4 ml/min) began with 2% B held for
1 minute, followed by an increase to 15%B over 2 minute, and to 30%B over the
next 7 minute. The column was washed with 95% B for 1.5 minute and then re-
equilibrated with 2% B for 2 minutes before the next injection.
To detect the in silico-selected candidate signature peptides, product ion scans
were set up using selected precursor ions corresponding to the doubly protonated
ions of the candidate peptides in the Q1 quadrupole, fragmenting these precursor
ions with a collision energy ramp (15–40 V) in the Q2 quadrupole, and mass
analysis of the product ions in the Q3 quadrupole mass analyzer under a scan rate
of 5000 amu/s. Extracted product ion (EPI) chromatograms of all the possible y
ions of each candidate peptide were generated using Masslynx (Version 4.1;
Waters) to allow visual inspection for product ion screening. A salient peak
shared by most or all y ion EPI chromatograms verified the detection of the
corresponding signature peptide. Upon detection verification, the signature
peptide sequences were sent for synthesis (Thermo Scientific).
UPLC-MRM Analysis. Lyophilized stable isotope-labeled signature pep-
tides were dissolved in 1 mL of 1:1 (v/v) acetonitrile:water solution. The solution
was diluted further to approximately 2–4 mg/ml and then infused into the Xevo
TQ-SMS at 5ml/min with an LC flow of 50%B at 0.4 ml/min. MRMparameters
were optimized using IntelliStart (Waters) under positive electrospray ion mode:
capillary voltage, 1.5 kV; cone voltage, 40 V; source offset, 40 V; dissolvation
temperature, 500C; dissolvation gas, 1000 l/h; nebulizer gas, 7 bar. The
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optimum collision energy and precursor/production masses for the signature
peptides are summarized in Table 1. UPLC-MRM quantification was performed
using the peak area ratios of signature peptides to corresponding stable isotope-
labeled signature peptides (internal standards).
Preparation of Calibration Standards. Two types of calibration standards
were prepared for the absolute quantification of FMOs in HLM. First,
recombinant FMO1, FMO3, and FMO5 Supersomes of known concentrations
(based on FAD content) were used to build calibration standards (0.005 to
20 pmol/digestion). Quality controls (QCs), consisting of FMO Supersomes at
0.2, 1, and 10 pmol/digestion, were prepared in triplicate. All recombinant
protein standards and QCs were denatured, alkylated, and trypsin-digested as
described above before UPLC-MRM analysis. Because of the varying amount
of total proteins in the standards, additional trypsin (2 mg total) was used to keep
the protein:trypsin ratio #30:1 in the high concentration standards. Second,
synthetic signature peptides of known concentrations (based on amino acid
analysis) were used to build calibration standards (0.02 to 20 pmol/digestion). To
normalize total protein loading, control Supersomes (30 mg) were spiked into the
peptide standards. The spiked peptide standards also were denatured, alkylated,
and trypsin-digested before UPLC-MRM analysis. The lower limit of quanti-
fication was defined as the lowest standard concentration with signal-to-noise
ratio .5 and acceptable precision and accuracy (within 20%).
FMO Marker Substrate Activity Assay. Cimetidine sulfoxidation was used
to measure FMO functional activity as described previously (Cashman et al., 1993;
Overby et al., 1997). Cimetidine (1mM; reportedKm values are 4mM for FMO3 and
.10mMfor FMO5)was preincubatedwithHLM (0.1mg/mL) in a phosphate buffer
(pH 7.4, 100 mM) containing 3.3 mMMgCl2 for 5 minutes at 33C. Although these
conditions were different from what was used by Zane et al. (submitted manuscript),
i.e., substrate concentration and incubation temperature, they served the purpose of
validating protein quantification by correlating marker substrate activity and protein
expression. Reactions (200ml final volume)were initiated by the addition ofNADPH
(1 mM final concentration). Aliquots (10 ml each) were removed from each reaction
at 1 and 5 minutes and transferred to tubes containing ice-cold acetonitrile (300 ml)
and famotidine sulfoxide (10 nM; internal standard). Quenched reaction mixtures
were centrifuged (2250 g for 20 minutes at 4C), and the resulting supernatants
(100ml) were dried under nitrogen at 50C. The dried samples were reconstituted
in water (150 mL) before UPLC-MS/MS quantification of cimetidine sulfoxide
using the Xevo TQ-S triple-quadrupole MS operated under positive electrospray
ion mode. Analytes were separated on a reversed-phase analytical column
(Thermo Scientific Aquasil C18, 2.1  50 mm, 3 mm; Bellefonte, PA). The
gradient (0.4 ml/min) began at 0% B for 0.5 minutes, then quickly increased to
5%B andwas held there for 3 minutes. The columnwas washedwith 100%B for
1 minute and re-equilibrated at 0% B for 0.5 minutes before the next injection.
UPLC-MS/MS quantification was performed using the peak area ratios of
cimetidine sulfoxide to famotidine sulfoxide. Cimetidine sulfoxide calibration
standards ranged from 0.1 to 100 mM. Cimetidine sulfoxidation rates were
determined from the amount of metabolite generated between the 1- and
5-minute reaction times. Cimetidine sulfoxide formation was linear for a minimum
of 30 minutes under the described conditions (data not shown). Because FMO
enzymes are heat labile in the absence of NADPH, their stability was examined
during the preincubation (5 minutes at 33C) with substrate only. Results showed
no significant difference in cimetidine sulfoxidation activities of recombinant
FMO1, FMO3, and the pooled HLM between preincubation with substrate
cimetidine only and preincubation with NADPH (data not shown), indicating
stability of FMO enzymes during the preincubation with substrate only.
Data Analysis. The final FMO protein concentration was the average value
determined using two signature peptides for each FMO protein. All average
values were calculated as the mean. For correlation analysis, measured
cimetidine sulfoxide formation rates in HLM were plotted versus FMO protein
concentration in the same sample, and the Pearson r and P values were reported
because all relevant data passed normality test (Supplemental Table 3). The slope
and Y-intercept values were determined by least-square linear regression
analysis. Student’s t tests (two-tailed, unpaired) were used to compare the pairs
of signature peptides. One-way analysis of variance followed by post hoc test
using Tukey’s adjustment was used to compare FMO5 expression in the fetal,
pediatric, and adult HLM. P, 0.05 was considered significant. All data analyses
were performed using GraphPad Prism (v. 5.0; San Diego, CA).
Results
Verification of Signature Peptides by Post-In Silico Product Ion
Screening. After the initial in silico selection of human FMO3 signature
peptides, eight candidate peptides (Supplemental Table 2) satisfied every
selection criteria described previously (Wang et al., 2008; Peng et al., 2015).
To select the final signature peptides (two for each protein) from the
candidate peptides, recombinant FMO3 was reduced, alkylated, and
trypsinized, and the resulting digest was separated on a UPLC analytical
column. Analysis was completed through product ion screening of the
doubly charged ions of the candidate peptides. Representative EPI
chromatograms of predicted y ions for the two final FMO3 signature
peptides selected for use in this study (FMO3_pep1_L and FMO3_pep4_L;
Table 1) are shown in Fig. 1, A and B, respectively. The signature peptides
produced salient peaks in each EPI chromatogram (2.5-minute peak for
FMO3_pep1_L and 5.5-minute peak for FMO3_pep4_L) and the product
ionmass spectra integrated across the peaksmatched each peptide sequence
(Fig. 1, C andD). In addition, EPI chromatograms of predicted y ions for the
remaining six FMO3 candidate signature peptides are shown in (Supple-
mental Fig. 1). Likewise, EPI chromatograms of predicted y ions for the final
TABLE 1
Signature peptides for human FMO1, FMO3, and FMO5
Protein Signature Peptidea Peptide Sequenceb Start-Endc Average Mass MH+d
MRM (m/z)
CE
Precursor Ion Product Ion
Da V
FMO1 FMO1_pep1_L FTEHVEEGR 43–51 1104.2 552.5 589.3 (y5) 20
FMO1_pep1_H FTEHVEEG(R) 1114.2 557.5 599.3 (y5) 20
FMO1_pep2_L VEDGQASLYK 345–354 1110.2 555.5 881.5 (y8) 15
FMO1_pep2_H VEDGQASLY(K) 1118.2 559.6 889.5 (y8) 15
FMO3 FMO3_pep1_L FSDHAEEGR 43–51 1048.1 524.5 561.3 (y5) 20
FMO3_pep1_H FSDHAEEG(R) 1058.1 529.5 571.3 (y5) 20
FMO3_pep4_L SNDIGGLWK 34–42 990.1 495.4 560.3 (y5) 15
FMO3_pep4_H SNDIGGLW(K) 998.1 499.4 568.3 (y5) 15
FMO5 FMO5_pep1_L FQENPEEGR 44–52 1106.1 553.4 587.3 (y5) 18
FMO5_pep1_H FQENPEEG(R) 1116.1 558.4 597.3 (y5) 18
FMO5_pep6_L WATQVFK 388–394 880.0 440.5 622.4 (y5) 10
FMO5_pep6_H WATQVF(K) 888.0 444.5 630.4 (y5) 10
aL and H indicate unlabeled and stable isotope-labeled peptides, respectively.
bStable isotope-labeled amino acid residues are included in parentheses.
cStart and end residue positions of peptides in the corresponding full-length protein.
dTheoretical average mass of mono-protonated molecular ion.
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FMO1 and FMO5 signature peptides (Table 1) also were examined and
verified for optimal UPLC-MRM detection (data not shown).
After identification and verification of the predicted signature
peptides, unlabeled signature peptides and corresponding 13C and 15N
stable isotope-labeled signature peptides (Table 1) were synthesized
and used for the development and optimization of a UPLC-MRM
method. This method allows for the multiplexed detection and
quantification of FMO1, FMO3, and FMO5 in HLM. Representative
UPLC-MRM chromatograms of signature peptides in tryptic digests of
adult HLM and fetal HLM are shown in Fig. 2.
Effects of Trypsin Digestion Time and Protein:Trypsin Ratio.
To optimize trypsin digestion conditions and determine the dynamic
range, the effects of digestion time and protein:trypsin ratio on the
absolute quantification of FMOs in pooled HLM were evaluated using
the developed UPLC-MRM method. The relative UPLC-MRM signals
of the signature peptides reached a maximum after 4 hours of digestion
and plateaued (or decreased slightly in some cases) thereafter (Fig. 3, A
and B). Because of the low expression of FMO1 in pooled HLM, only
one of the two FMO1 signature peptides was detected and evaluated
(Fig. 3B). As a result, tryptic digestion was carried out for 4 hours for
the remainder of the study. In addition, the relative UPLC-MRM signals
of the signature peptides increased linearly with respect to HLM protein
loading between 10 to 100 mg when 1 mg trypsin was used (Fig. 3, C
and D); however, a slight downward deviation was noticed above 50mg
of HLM protein. Thus, optimized trypsin digestion conditions, 4 hours
digestion and 30:1 protein:trypsin ratio, were selected and used for the
absolute quantification of FMO1, FMO3, and FMO5 in HLMs.
Absolute Quantification of FMO3 and FMO5 in Adult HLM
and Correlation to Marker Substrate Activity. Similar to the
immunoquantification and targeted proteomic quantification of CYPs
(Wang et al., 2008; Michaels and Wang, 2014), recombinant FMO
Supersomes of known concentrations were used initially to create
calibration standards. The concentrations of the recombinant FMO Super-
somes, based on FAD content, were provided by the vendor. The
calibration curves for each recombinant FMOSupersome (0.01 to 4 pmol/
digestion; 10–12 concentrations) demonstrated good linearity (r2. 0.99).
Fig. 1. Post-in silico product ion screening of FMO3 signature peptides (FMO3_pep1_L and FMO3_pep4_L). Extracted product ion chromatograms of predicted y ions (A
and B) and MS/MS spectra (C and D) of the detected FMO3 signature peptides are shown after product ion screening analysis of a recombinant FMO3 Supersomes tryptic
digest (40.5 pmol FMO or 50 mg total protein). FMO3_pep1_L and FMO3_pep4_L eluted at 2.5 and 5.5 minutes, respectively.
978 Chen et al.
By using 30 mg of HLM, the observed lower limit of quantification for
the three FMOs was 0.33 pmol/mg HLM protein. The intraday accuracy
(percent deviation) and precision (CV) of the analytical method, based on
QC samples, were within 15%.
Method coherence was evaluated by comparing protein quantifica-
tion results from two different signature peptides of the same protein
(i.e., FMO3_pep1_L versus FMO3_pep4_L and FMO5_pep1_L versus
FMO5_pep6_L). In each case, a strong correlation, near-unity slope
and near-zero Y-intercept were observed (Fig. 4, B and C), indicating
consistent protein quantification results between the different signature
peptides. In addition, good coherence was observed for two FMO1
signature peptides when fetal HLM were analyzed (Fig. 4A; described
below). As a result, final protein concentrations were calculated as the
average of the quantification results from the two signature peptides.
By using a panel of adult HLM (n = 9 individual donors and 1 pooled),
the protein concentrations of the three FMOs were determined using the
developed targeted quantitative proteomic method. The FMO1 concen-
tration in adult HLM was below the lower limit of quantification (,0.33
pmol/mg HLM protein). The final FMO3 and FMO5 average protein
concentrations (range and 95% confidence interval [CI]) were 46 (26–65
and 36–56) and 27 (11.5–49 and 18.5–36) pmol/mg HLM protein,
respectively. Furthermore, cimetidine sulfoxidation activities were mea-
sured in the HLM panel and compared with FMO protein concentrations.
A strong correlation was observed between cimetidine sulfoxidation
activity and FMO3 protein concentration (r2 = 0.86, P = 0.0001; Fig. 5A)
but not FMO5 protein concentration (r2 = 0.30, P = 0.103; Fig. 5B).
Absolute Quantification of FMO1 and FMO5 in Fetal HLM and
Correlation to Marker Substrate Activity. To evaluate the method
for absolute quantification of FMO1, a panel of fetal HLM (n = 7
individual donors) was analyzed; the adult HLM panel lacked FMO1
expression. The final FMO1 average protein concentration (range and
95%CI) in the fetal HLM panel was 7.0 (4.9–9.7 and 5.2–8.7) pmol/mg
HLM protein. In addition, there were appreciable amounts of FMO5,
which averaged 21 (14–32 and 14–29) pmol/mg HLM protein (Fig. 6A).
In contrast to adult HLM, FMO3 was barely above lower limit
of quantification (0.33 pmol/mg HLM protein) in fetal HLM, averaging
Fig. 2. Representative MRM chromatograms of FMO signature peptides in tryptic
digests of adult (A) and fetal (B) HLM. Digestion mixtures, containing 30 mg HLM
and 1 mg trypsin, were incubated for 4 hours at 37C before UPLC-MRM analysis.
Fig. 3. Effects of trypsin digestion time and
HLM protein loading on the UPLC-MRM
signals of FMO signature peptides derived
from pooled HLM. The UPLC-MRM peak
areas of FMO signature peptides were normal-
ized by those of corresponding stable isotope-
labeled signature peptides spiked in as internal
standard. For the digestion time study (A and
B), each reaction contained 30 mg of pooled
HLM and 1 mg of trypsin. For the protein
loading study (C and D), each reaction contained
1 mg of trypsin and varying amounts of HLM
proteins. Symbols and error bars represent
the mean and standard deviation of triplicate
determinations. In many cases, error bars are
too small to be seen. Dashed lines (C and D)
represent the best-fit lines of least-square
linear regression analysis.
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0.7 pmol/mg HLM protein with a highest concentration of 2.2 pmol/mg
HLM protein. In addition, cimetidine sulfoxidation activity also was
measured in the fetal HLM panel and compared with FMO protein
concentrations. Neither FMO1 (r2 = 0.41,P = 0.12) nor FMO5 (r2 = 0.01,
P = 0.83) protein concentration correlated with the marker substrate
activity (data not shown). Because FMO5 was reported to lack
appreciable cimetidine sulfoxidation activity (Overby et al., 1997; Hai
et al., 2009), correlation using a relative activity factor-adjusted FMO
expression was not attempted.
FMO5 Expression in Fetal, Pediatric, and Adult HLM. In
addition to fetal and adult HLM described above, a panel of pediatric
HLM (n = 16 individual donors; Supplemental Table 1) was analyzed
for FMO1, FMO3, and FMO5 expression. The FMO1 and FMO3
expression in the pediatric HLM has been reported (Zane et al.,
submitted manuscript). The final FMO5 average protein concentration
(range and 95% CI) in the pediatric HLM panel was 36.2 (2.9–110 and
20.1–52.3) pmol/mg HLM protein (Fig. 6B). There was no statistically
significant difference among the three age groups (P = 0.317; Fig. 6C).
Comparison of Recombinant Proteins versus Synthetic Peptides
as Calibration Standards for Absolute Quantification. Previously,
our laboratory and others reported signature peptide-dependent abso-
lute quantification of CYPs and drug transporters using synthetic
peptides as calibration standards (Wang et al., 2008; Balogh et al.,
2013; Michaels andWang, 2014; Prasad et al., 2014; Peng et al., 2015).
To assess such a scenario for the absolute quantification of FMOs, two
signature peptides were selected for each FMO isozyme (Table 1), and
quantification coherence between the two peptides was evaluated.
When recombinant FMO Supersomes of known concentration were
used to generate signature peptide standards, good coherence was
observed, as described above (Fig. 4). However, when synthetic
peptides of known concentrations were used to generate signature
peptide standards, good coherence was observed for FMO1 but not for
FMO3 or FMO5 (Fig. 7).
Absolute FMO concentrations measured using synthetic peptide
standards were substantially greater than those determined using
recombinant protein standards (i.e., Supersomes) (Fig. 7 versus Fig. 4).
For example, the average FMO1 concentration in fetal HLM was
7.0 pmol/mg HLM protein with recombinant protein standards. In
contrast, it was 29 or 32 pmol/mg HLM protein (4- to 5-fold higher) with
synthetic FMO1_pep1_L or FMO1_pep2_L standards, respectively.
Similarly, the average FMO3 and FMO5 concentrations in adult HLMs
were 46 and 27 pmol/mg HLM protein, respectively, with recombinant
protein standards. In contrast, they were 259 or 412 pmol/mg HLM
protein (5.6- to 9-fold higher) for FMO3 with synthetic FMO3_pep1_L
or FMO3_pep4_L standards and 21 or 32 pmol/mg HLM protein (0.8-
to 1.2-fold higher) for FMO5 with synthetic FMO5_pep1_L or
FMO5_pep6_L standards.
Absolute Quantification of FMOs in Recombinant FMO
Supersomes using Synthetic Peptide-Generated Calibration Stan-
dards. To further investigate discrepancies in the absolute quantifica-
tion of FMOs when recombinant proteins versus synthetic peptides
were used as standards and determine the ratios of holoprotein versus
total protein, total FMO protein was quantified in recombinant FMO
Supersomes of different concentrations using synthetic peptides as
calibration standards. The measured total FMO protein amount was
plotted against the nominal FMO protein amount based on FAD
Fig. 4. Coherence analysis of FMO protein quantification by UPLC-MRM-based targeted proteomic approach using different signature peptides and recombinant FMO
Supersomes-generated calibration standards. Quantification of FMO1 (A) was performed using the fetal HLM panel, whereas quantification FMO3 (B) and FMO5 (C) was
performed using the adult HLM panel. Symbols and error bars represent the mean and standard deviation of triplicate determinations for an individual donor HLM. In many
cases, error bars are too small to be seen. Dotted lines represent the best-fit lines of least-square linear regression analysis.
Fig. 5. Correlation analysis of FMO3 (A) and FMO5 (B)
protein content and measured marker activity in the adult
individual donor HLM panel. Symbols and error bars
represent the mean and standard deviation of triplicate
determinations for an individual donor HLM. In many
cases, error bars for protein concentration are too small to
be seen. Dotted lines represent the best-fit lines of least-
square linear regression analysis.
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content, which represents the FMO holoprotein (Fig. 8). Similar to the
previously described signature peptide-dependent quantification, the
ratio of total protein versus holoprotein (slopes in Fig. 8) for each
recombinant FMO Supersomes also was dependent upon the signature
peptide used. The ratio ranged from 5.0 to 5.6 for FMO1, 6.0 to 8.4 for
FMO3, and 0.9 to 1.5 for FMO5.
Discussion
In this study, a UPLC-MRM-based targeted quantitative proteomic
method has been developed for the multiplexed absolute quantification
of FMOs 1, 3, and 5 in HLM. This method has a lower limit of
quantification of 0.33 pmol/mg HLM protein for each FMO when
30 mg of HLM is used. By using the developed quantitative proteomic
method, protein concentrations of the three FMOs were determined in
three panels of HLM, one derived from adult livers (n = 10), one from
pediatric livers (n = 16), and one from fetal livers (n = 7). In the adult
HLM, FMO3 was more abundant than FMO5 (46 versus 27 pmol/mg
HLM protein), which supports earlier reports (Cashman, 1995, 2000)
but not the most recent report (Cashman and Zhang, 2006), both of
which were based on mRNA expression. FMO1 was below the lower
limit of quantification (0.33 pmol/mg HLM protein). In the fetal HLM
(14–20 weeks gestation), FMO1 was expressed at relatively high levels
(7.0 pmol/mg HLM protein), similar to what was reported previously
(7.8 pmol/mgHLM protein; 8–15weeks gestation) (Koukouritaki et al.,
2002). FMO3 was barely above the lower limit of quantification,
averaging 0.7 pmol/mg HLM protein. Interestingly, FMO5 was the
predominant FMO isozyme in fetal HLM, averaging threefold greater
protein expression than FMO1 (21 versus 7.0 pmol/mg HLM protein).
In the pediatric HLM, FMO5 also appeared to be the predominant FMO
isozyme (36.2 versus 20.0 pmol/mg HLM protein for FMO3), whereas
FMO1 was barely detected (Zane et al., submitted manuscript).
Although FMO5 expression was not significantly different among the
three age groups, larger interindividual variability was observed in the
pediatric HLM (38-fold versus 4.3- and 2.3-fold in adult and fetal HLM,
respectively) (Fig. 6). These targeted quantitative proteomic results
confirm previous reports that FMO1 and FMO3 expression undergo a
developmental transition and also discovered that FMO5 has relatively
stable expression throughout development. However, these results
should be interpreted with caution, because our study only included a
small number of HLM from each age group, fetal samples only
represented the second trimester, and neonatal samples (birth to first
month) were absent (Supplemental Table 1). As such, future studies
employing larger panels of HLM are warranted.
LC-MRM-based targeted quantitative proteomic methods for the
absolute quantification of CYPs, UDP-glucuronosyltransferases, and
drug transporters were first reported in the late 2000s (Fallon et al.,
2008; Kamiie et al., 2008; Li et al., 2008; Wang et al., 2008). These
methods rely on the identification and detection of signature peptides
for each target protein. The selection and verification of suitable
signature peptides can be time-consuming and costly, mainly because
of peptide synthesis after in silico selection. The ability to verify LC-
MRM detection of the selected signature peptides in a protein digest
before committing to peptide synthesis is therefore desirable. As such,
Fig. 6. Comparison of FMO5 protein expression in the fetal, pediatric, and adult HLM. FMO5 protein concentration was determined by UPLC-MRM-based targeted
proteomic approach using recombinant FMO5 Supersomes-generated calibration standards. Donor age (gestational [A] and postnatal [B] age) was plotted in logarithm scale.
Symbols in the scatterplots represent the mean of triplicate determinations of an individual HLM sample. Lines and error bars represent the mean and standard deviation of all
HLM samples in an age group. One-way analysis of variance was used to compare all three age groups (C; P = 0.317).
Fig. 7. Comparison of FMO protein quantification by UPLC-MRM-based targeted proteomic approach using different signature peptides and synthetic signature peptide-
generated calibration standards. Symbols represent the mean of triplicate determinations for an individual donor HLM. Lines and error bars represent the mean and standard
deviation for a panel of HLM. Student’s t tests (two-tailed, unpaired) were used to compare the pairs of signature peptides for FMO1 (A), FMO3 (B), and FMO5 (C).
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we implemented a post-in silico product ion screening step to verify the
detection of selected signature peptides (Fig. 1) before their synthesis to
reduce unnecessary peptide synthesis and costs. For example, only two
FMO3 signature peptides (FMO3_pep1_L and FMO3_pep4_L) were
synthesized in this study, rather than all eight candidate signature
peptides (Supplemental Table 2).
To achieve absolute quantification using an LC-MRM-based
targeted proteomic approach, two types of standards are typically
employed, recombinant proteins of known concentration or synthetic
signature peptides of known concentration. Because of the poor
coherence (i.e., signature peptide-dependent quantification) when
synthetic peptides were employed as standards (Wang et al., 2008;
Balogh et al., 2013;Michaels andWang, 2014; Prasad et al., 2014; Peng
et al., 2015), we prefer to use recombinant proteins when available (e.g.,
CYPs) to generate standards and employ at least two signature peptides
for each protein to ensure quantification coherence. In the current study,
poor quantification coherence was observed for FMO3 and FMO5
when synthetic peptides were used as standards (Fig. 7, B and C).
Presumably, the presence of multiple acidic amino acid residues (D or
E) close to the tryptic cleavage sites (e.g., FMO1_pep1, FMO3_pep1
and FMO5_pep1; Table 1) could cause missed cleavage (Yen et al.,
2006), resulting in lower recovery of signature peptides and un-
derestimation of protein concentration. In contrast, quantification was
coherent between signature peptides for all three FMOs when
recombinant FMO Supersomes were used to generate standards (Fig.
4). Therefore, we recommend the use of recombinant proteins, when
available, to generate standards for LC-MRM-based targeted protein
quantification. Moreover, we call for a coordinated effort to produce
reference protein standards, especially in the case of drug transporters,
for use as calibration standards for targeted quantitative proteomics. It is
not completely understood yet what may cause the lack of coherence in
signature peptide-dependent quantification when synthetic peptides are
used as standards. We have proposed that different digestion efficien-
cies (e.g., missed cleavage) and/or unexpected posttranslational
modifications of signature peptides were the underlying causes (Peng
et al., 2015) and warrant future investigation.
FMOs, specifically the holoprotein, require an FAD prosthetic group
for catalytic activity. Recombinant FMO Supersomes can be quantified
based on their FAD content to give a holoprotein concentration. In
contrast, the use of synthetic peptides as standards for targeted
proteomic quantification provides a total protein concentration
(i.e., holoprotein + apoprotein) for a sample. Such a distinction was
seen (Fig. 8), because the total FMO protein amount exceeded its
nominal holoprotein amount 5- to 6.6-fold for FMO1 and 6- to 8.5-fold
for FMO3, whereas only a small difference (0.9- to 1.5-fold) was seen
for FMO5. These results suggest that a large portion of FMO1 and
FMO3 proteins in Supersomes is present as apoprotein without the
FAD prosthetic group, whereas most FMO5 proteins are holoproteins.
This is consistent with a much greater FAD content in FMO5
Supersomes (2700 pmol/mg protein; lot#3154943) relative to those in
FMO1 and FMO3 Supersomes (500 and 810 pmol/mg protein,
respectively; lot#3098891 and lot#3130681, respectively) reported by
the vendor, although differential expression efficiency also could
contribute to FAD content differences in FMO Supersomes.
For both conventional immunoquantification and the targeted
proteomic quantification described here, an assumption was made that
the holoprotein:apoprotein ratio remains the same between a recombi-
nant system (e.g., Supersomes) and HLM. However, this assumption
remains to be examined. Deviation from this assumption could result in
either underestimation or overestimation of enzymatic activity in HLM,
depending on how the ratio in HLM deviates relative to that in the
recombinant system. For example, if the ratio deviates upward in HLM
(i.e., higher proportion of holoproteins), this will result in an un-
derestimation of HLM holoprotein concentration, and the measured
HLM activity will exceed the predicted activity calculated as the
product of recombinant enzyme activity and HLM protein expression.
To test this, one could first determine the rate of a probe substrate
reaction, which needs to be catalyzed exclusively by the enzyme of
interest, in HLM and then compare the measured HLM activity with the
predicted activity based on the measured activity of the recombinant
enzyme and measured expression level of the enzyme in HLM. By
using FMO3 and cimetidine sulfoxidation as an example, the average
measured cimetidine sulfoxidation activity in the adult HLM panel was
1.25 nmol/min/mg HLM (Fig. 5A), the measured cimetidine sulfox-
idation activity of recombinant FMO3 was 6.0 nmol/min/nmol FMO3
(unpublished data), and the measured FMO3 expression in HLM was
0.046 nmol/mgHLM (Fig. 4B). The predicted activity is 0.28 nmol/min/mg
HLM, substantially less than the measured activity of 1.25 nmol/min/mg
HLM. Thus, an upward deviation of the holoprotein:apoprotein ratio
in HLMs could have contributed to the underprediction, in addition to
other possibilities proposed in the companion paper (Zane et al.,
submitted manuscript). The questionable assumption regarding the
holoprotein:apoprotein ratio for FMOs, as well as for CYPs, is
underappreciated and requires further investigation using newly
available analytical tools (e.g., targeted quantitative proteomics).
In summary, a UPLC-MRM-based targeted proteomic assay has
been developed for the absolute protein quantification of FMOs 1, 3,
and 5 in HLM. Our results corroborated the developmental transition in
FMO1 and FMO3 expression and revealed relatively stable FMO5
expression throughout development. The developed FMO assay and
Fig. 8. Comparison between total (holoprotein + apoprotein) FMO protein concentration and nominal holoprotein concentration in FMO1 (A), FMO3 (B), and FMO5 (C)
Supersomes. The total FMO protein concentration was determined using synthetic signature peptides as calibration standards, whereas the nominal holoprotein concentration
was determined based on FAD content (provided by the vendor). Dotted lines represent the best-fit lines of least-square linear regression analysis.
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other previously developed targeted quantitative proteomic assays are
expected to assist in addressing previously unanswered questions in
quantitative pharmacology.
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